tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Hansoh Pharmaceutical Group Company Limited (HK:3692)
HKEX:3692
Hong Kong Market
3692
Hansoh Pharmaceutical Group Company Limited
Stock Analysis
Analyst Forecasts
Technical Analysis
Chart
Earnings
Dividends
Ownership
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding HK:3692?
Track your performance easily
Link Broker

Hansoh Pharmaceutical Group Company Limited (3692) Stock Price & Analysis

1 Followers

3692 Stock Chart & Stats

Advanced Chart >
Day’s RangeHK$0 - HK$0
52-Week RangeHK$11.18 - HK$22.80
Previous CloseHK$18.52
Volume11.44M
Average Volume (3M)9.17M
Market Cap
HK$109.93B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)21.5
Beta0.97
Next Earnings
Apr 01, 2025
EPS Estimate
HK$0.24
Last Dividend Ex-Date
Sep 20, 2024
Dividend Yield1.88%
Share Statistics
EPS (TTM)0.86
Shares OutstandingN/A
10 Day Avg. Volume6,523,819
30 Day Avg. Volume9,171,849
Standard Deviation0.12
R-Squared0.21
Alpha0.00531
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)7.43
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$24.61
Price Target Upside32.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5

Hansoh Pharmaceutical Group Company Limited News

Hansoh Pharma’s Breakthrough in Cancer Drug Development
PremiumCompany Announcements
Hansoh Pharma’s Breakthrough in Cancer Drug Development
22d ago
3692
Hansoh Pharma’s Ameile Achieves Key Trial Success
PremiumCompany Announcements
Hansoh Pharma’s Ameile Achieves Key Trial Success
1M ago
3692
Hansoh Pharmaceutical Group Company Limited (3692) Unveils Dividend Details for Q4: Mark Your Calendar!
PremiumDividends
Hansoh Pharmaceutical Group Company Limited (3692) Unveils Dividend Details for Q4: Mark Your Calendar!
3M ago
3692
Hansoh Pharma Announces Mid-Year Dividend
PremiumCompany Announcements
Hansoh Pharma Announces Mid-Year Dividend
3M ago
3692
Hansoh Pharmaceutical Reports Soaring H1 2024 Profits
PremiumCompany Announcements
Hansoh Pharmaceutical Reports Soaring H1 2024 Profits
3M ago
3692
Hansoh Pharma’s Cancer Drug Fast-Tracked by FDA
PremiumCompany Announcements
Hansoh Pharma’s Cancer Drug Fast-Tracked by FDA
3M ago
3692
Hansoh Pharmaceutical’s New Drug Application Accepted
PremiumCompany Announcements
Hansoh Pharmaceutical’s New Drug Application Accepted
3M ago
3692
Hansoh Pharmaceutical Plans Key Board Meeting
PremiumCompany Announcements
Hansoh Pharmaceutical Plans Key Board Meeting
3M ago
3692
See More HK:3692 News >

Options Prices

Currently, No data available
---

Ownership Overview

2.68%95.48%
―
Insiders
2.68% Mutual Funds
― Other Institutional Investors
95.48% Public Companies and
Individual Investors
Detailed Ownership Overview >

3692 FAQ

What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$11.18 and its highest was HK$22.80 in the past 12 months.
    What is Hansoh Pharmaceutical Group Company Limited’s market cap?
    Currently, no data Available
    When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
    Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Apr 01, 2025 which is in 129 days.
      How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
      Hansoh Pharmaceutical Group Company Limited released its earnings results on Aug 27, 2024. The company reported HK$0.495 earnings per share for the quarter, beating the consensus estimate of HK$0.42 by HK$0.075.
        Is Hansoh Pharmaceutical Group Company Limited overvalued?
        According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Hansoh Pharmaceutical Group Company Limited pay dividends?
          Hansoh Pharmaceutical Group Company Limited pays a Annually dividend of HK$0.2 which represents an annual dividend yield of 1.88%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
            What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
            Hansoh Pharmaceutical Group Company Limited’s EPS estimate is HK$0.24.
              How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
              Hansoh Pharmaceutical Group Company Limited has 5,935,650,000 shares outstanding.
                What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
                Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.495 in its last earnings report, beating expectations of HK$0.42. Following the earnings report the stock price went up 1.348%.
                  Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
                  Currently, no hedge funds are holding shares in HK:3692
                  ---

                  Hansoh Pharmaceutical Group Company Limited Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Analyst Consensus

                  Strong Buy
                  Average Price Target:
                  HK$24.61 (32.88% Upside)

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  29.72%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  18.20%
                  Trailing 12-Months
                  Asset Growth
                  -1.24%
                  Trailing 12-Months
                  Top Smart Score Stocks >

                  Company Description

                  Hansoh Pharmaceutical Group Company Limited

                  Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified, and leading drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on the gastrointestinal and cardiovascular therapeutic areas.
                  ---

                  3692 Stock 12 Month Forecast

                  Average Price Target

                  HK$24.61
                  ▲(32.88% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"HK$12","31":"HK$31","16.75":"HK$16.75","21.5":"HK$21.5","26.25":"HK$26.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$24.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$17.95</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,16.75,21.5,26.25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.84,18.775384615384617,19.71076923076923,20.646153846153847,21.58153846153846,22.516923076923078,23.45230769230769,24.38769230769231,25.323076923076922,26.25846153846154,27.193846153846152,28.12923076923077,29.064615384615387,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.84,18.36076923076923,18.88153846153846,19.40230769230769,19.923076923076923,20.443846153846152,20.964615384615385,21.485384615384614,22.006153846153847,22.526923076923076,23.04769230769231,23.568461538461538,24.089230769230767,{"y":24.61,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.84,17.84846153846154,17.856923076923078,17.865384615384617,17.873846153846152,17.88230769230769,17.89076923076923,17.89923076923077,17.907692307692308,17.916153846153847,17.924615384615382,17.93307692307692,17.94153846153846,{"y":17.95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.38,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":14.41,"date":1700179200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.59,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.67,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.04,"date":1710460800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.57,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.91,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.47,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.47,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.68,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Detailed Analyst Forecast >

                  Technical Analysis

                  Overall Consensus
                  Buy
                  12Bullish
                  6Neutral
                  4Bearish
                  Bullish
                  Neutral
                  Bearish
                  Overall Consensus
                  12
                  6
                  4
                  Technical Analysis
                  3
                  6
                  1
                  Moving Averages
                  9
                  0
                  3
                  Technical Analysis >
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  1167
                  Jacobio Pharmaceuticals Group Co., Ltd.
                  ―
                  ―
                  2616
                  CStone Pharmaceuticals
                  ―
                  ―
                  Compare HK:3692 Stocks >

                  Best Analysts Covering 3692

                  1 Year
                  Linda ShuHSBC
                  1 Year Success Rate
                  3/3 ratings generated profit
                  100%
                  1 Year Average Return
                  +62.47%
                  reiterated a buy rating 8 months ago
                  Copying Linda Shu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +62.47% per trade.
                  Best Analyst Covering >
                  Popular Stocks
                  ---

                  Become an Expert with TipRanks Premium

                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis
                  Subscribe NowSee Plans & Pricing